Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 6, 1998, Pages 477-484

  Reid, Joel M ^a   Kovach, John S ^a   O'Connell, Michael J ^a   Bagniewski, Pamela G ^a   Moertel, Charles G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Levamisole; Pharmacokinetics; Toxicity

Indexed keywords

4' HYDROXYLEVAMISOLE; DRUG METABOLITE; FLUOROURACIL; LEVAMISOLE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; FEMALE; HUMAN; INJECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CONFUSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; LEVAMISOLE; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0031935625     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050770     Document Type: Article

References (13)

1. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. (1995) Fluorouracil plus levumisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321-326
3. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR (1991) Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 9: 2052-2066
4. Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, Moertel CG, Rodriguez M (1992) Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 31: 262 267
5. Kovach JS, Svingen P, McGovern R (1990) Levamisole preferentially potentiates the antiproliferative activity of 5-fluorouracil compared to 5-fluoro-2'deoxyuridine in vitro. Proc Am Assoc Cancer Res 31: 399
6. Kovach JS, Svingen PA, Schaid DJ (1992) Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatasc. J Natl Cancer Inst 84: 515-519
7. Luyckx M, Rousseau F, Cazin M, Brunet C, Cazin JC, Haguenoer JM, Devulder B, Lesieur I, Lesieur D, Gosselin P, Adenis L, Cappelaere P, Demaille A (1982) Pharmacokinetics of levamisole in healthy subjects and cancer patients. Eur J Drug Metab Pharmacokinet 7: 247-254
8. Graziani G, De Martin GL (1997) Pharmacokinetic studies on levamisole. Absorption, distribution, excretion and metabolism of levamisole in animals a review. Drues Exp Clin Res 2: 221 233
9. Kouassi E, Caile G, Lery L, Lariviere L, Vezina M (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisolc in human plasma and urine. Biopharm Drug Dispos 7: 71-89
10. Gibaldi M, Perrier D (1982) Non compartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 409-417
11. Schnieden H (1981) Levamisole a general pharmacological perspective, Int J Immunopharm 3: 9-13
12. Adams JG (1978) Pharmacokinetics of levamisole. J Rheumatol 5: 137-142
13. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA (1993) Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11: 2386-2390